The Watershed Moment for ADCs has Arrived

Ten years ago, antibody-drug conjugates (ADCs) were being talked about as the next big breakthrough in pharmaceuticals due to their highly targeted approach, especially in areas such as oncology. When Adcetris® became the second ADC approved by the U.S. Food and Drug Administration (FDA) in 2011, it was predicted to be a watershed moment when the floodgates would open for more novel ADC approvals...
Two-Part Podcast Series
Part 1: The benefits of using a single-source for discovery, development and GMP manufacture of antibody drug conjugates and other novel bioconjugates
Part 2: Streamline the ADC Path to the Clinic with One-stop Drug Development and Critical Technology Advancements


Hear Jimmy Li, Ph.D., CEO of WuXi XDC, a WuXi Biologics subsidiary, describes why a single-source ADC development platform can expedite bioconjugate drug development and simplify R&D and the supply chain.
In part 2, Jimmy Li, Ph.D., discusses on how a one-stop drug development organization greatly streamlines ADC development and also reviews new technologies advancing the field of antibody drug conjugates. 
The WuXi XDC comprehensive technology platform provides for our clients an integrated one-stop value chain for the development of ADCs and other bioconjugates. To learn more, watch it now:
World ADC London 2022
Date: Mar 29-Apr 1, 2022
Location: London, UK
PEGS Boston
Date: May 2-6, 2022
Location: Boston, MA
For more information visit our website at www.wuxibiologics.com
or email us at [email protected]. 
For worldwide career opportunities visit us today.
Follow Us!